JPH10509319A - ドーパミン作動性細胞のインビトロ誘導 - Google Patents
ドーパミン作動性細胞のインビトロ誘導Info
- Publication number
- JPH10509319A JPH10509319A JP8515599A JP51559996A JPH10509319A JP H10509319 A JPH10509319 A JP H10509319A JP 8515599 A JP8515599 A JP 8515599A JP 51559996 A JP51559996 A JP 51559996A JP H10509319 A JPH10509319 A JP H10509319A
- Authority
- JP
- Japan
- Prior art keywords
- cells
- dopaminergic
- growth factor
- tissue
- family
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0619—Neurons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0623—Stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0676—Pancreatic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
- C12Y114/16—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with reduced pteridine as one donor, and incorporation of one atom of oxygen (1.14.16)
- C12Y114/16002—Tyrosine 3-monooxygenase (1.14.16.2)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
- C12N2500/24—Iron; Fe chelators; Transferrin
- C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/11—Epidermal growth factor [EGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/148—Transforming growth factor alpha [TGF-a]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/16—Activin; Inhibin; Mullerian inhibiting substance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/08—Coculture with; Conditioned medium produced by cells of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Neurology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Microbiology (AREA)
- Developmental Biology & Embryology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Psychology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.インビトロで、神経細胞におけるチロシンヒドロキシラーゼの発現を誘導す る方法であって、該細胞を、線維芽細胞成長因子ファミリーの少なくとも1種と 、条件培地及びトランスフォーミング成長因子ベータファミリーのメンバーから なる群より選ばれる少なくとも1種の添加物とを含む培養培地と接触させること を特徴とする方法。 2.前記培養培地が定義されており、前記線維芽細胞成長因子ファミリーのメン バーがFGF−2であり、かつ前記添加物がアクチビン及び骨形成タンパク質2 からなる群より選ばれるトランスフォーミング成長因子ベータファミリーのメン バーである請求の範囲第1項記載の方法。 3.前記神経細胞を、ポリ−D−リジン、ポリ−L−オルニチン、マトリゲル、 ラミニン及びフィブロネクチンからなる群より選ばれるイオン的に荷電した表面 上で培養する請求の範囲第1項記載の方法。 4.前記荷電した表面がポリ−L−オルニチンである請求の範囲第3項記載の方 法。 5.前記神経細胞を通常非ドーパミン作動性神経組織から得る請求の範囲第1項 記載の方法。 6.前記通常非ドーパミン作動性神経組織が線条体及び皮質からなる群より選ば れる請求の範囲第5項記載の方法。 7.前記添加物が星状細胞の条件培地及び膠細胞の条件培地からなる群より選ば れる条件培地である請求の範囲第1項記載の方法。 8.前記条件培地がラットB49膠細胞系に由来する請求の範囲第7項記載の方 法。 9.前記条件培地が更に血清を含む請求の範囲第1項記載の方法。 10.前記神経細胞を支持層の存在なしに培養する請求の範囲第1項記載の方法。 11.前記神経細胞が胚組織から得た初代細胞である請求の範囲第1項記載の方法 。 12.前記神経細胞が、増殖誘導成長因子の存在下、インビトロで増殖した少なく とも1種の多分化能神経幹細胞の子孫である請求の範囲第1項記載の方法。 13.前記多分化能神経幹細胞が成熟した神経組織に由来する請求の範囲第12項 記載の方法。 14.インビトロで、初代神経細胞におけるチロシンヒドロキシラーゼの発現を誘 導する方法であって、線維芽細胞成長因子ファミリーのメンバー及びトランスフ ォーミング成長因子ベータファミリーの少なくとも1種のメンバーからなる定義 された培養培地中、該神経細胞を、ポリ−D−リジン、ポリ−L−オルニチン、 マトリゲル、ラミニン及びフィブロネクチンからなる群より選ばれるイオン的に 荷電した表面と接触させることを特徴とする方法。 15.前記線維芽細胞成長因子ファミリーのメンバーがFGF−2であり、かつ前 記トランスフォーミング成長因子ベータファミリーのメンバーがアクチビン及び 骨形成タンパク質2からなる群より選ばれる請求の範囲第14項記載の方法。 16.前記初代神経細胞を通常非ドーパミン作動性神経組織から得る請求の範囲第 14項記載の方法。 17.通常非ドーパミン作動性神経組織から得た神経細胞におけるチロシンヒドロ キシラーゼの発現を誘導する方法であって、該細胞を、支持細胞層及び線維芽細 胞成長因子を含有する培養培地と接触させることを特徴とする方法。 18.前記支持細胞層が通常非ドーパミン作動性神経組織に由来する請求の範囲第 17項記載の方法。 19.前記培養培地が更に血清を含む請求の範囲第17項記載の方法。 20.前記神経細胞が、成長因子の存在下、インビトロで増殖した少なくとも1種 の多分化能神経幹細胞の子孫である請求の範囲第17項記載の方法。 21.前記通常非ドーパミン作動性組織が線条体及び皮質からなる群より選ばれる 請求の範囲第17項記載の方法。 22.前記培養培地が更に条件培地を含む請求の範囲第17項記載の方法。 23.前記条件培地が膠細胞に由来する請求の範囲第22項記載の方法。 24.前記条件培地が星状細胞に由来する請求の範囲第22項記載の方法。 25.前記条件培地がラットB49膠細胞系に由来する請求の範囲第22項記載の 方法。 26.前記培養培地が更に血清からなる請求の範囲第18項記載の方法。 27.ドーパミン作動性細胞を要求する患者における神経障害を治療する方法であ って、分化する又は分化したドーパミン作動性細胞を、該患者のドーパミン作動 性細胞を要求するCNS領域に移植することからなり、該分化する又は分化した ドーパミン作動性細胞が、神経細胞を、線維芽細胞成長因子ファミリーのメンバ ー及びトランスフォーミング成長因子ベータファミリーの少なくとも1種のメン バーからなる培養培地と接触させることにより形成されることを特徴とする方法 。 28.前記患者がパーキンソン病を患っており、前記分化する又は分化したドーパ ミン作動性細胞を前記患者の線条体に投与する請求の範囲第27項記載の方法。 29.前記線維芽細胞成長因子ファミリーのメンバーがFGF−2であり、かつ前 記トランスフォーミング成長因子ベータファミリーのメンバーがアクチビン及び 骨形成タンパク質からなる群より選ばれる請求の範囲第27項記載の方法。 30.前記培養培地が定義されている請求の範囲第27項記載の方法。 31.前記神経細胞を前記患者のCNSから得る請求の範囲第27項記載の方法。 32.薬剤のドーパミン作動性細胞に対する効果をスクリーニングする方法であっ て、a)神経組織由来の神経細胞を、線維芽細胞成長因子ファミリーの少なくと も1種のメンバーと、条件培地及びトランスフォーミング成長因子ベータファミ リーのメンバーからなる群より選ばれる少なくとも1種の添加物とからなる培養 倍地中で培養し、ドーパミン作動性細胞を生成し、 b)薬剤を前記度細胞に投与し、 c)該薬剤の該ドーパミン作動性細胞に対する効果を見る、 ことを特徴とする方法。 33.前記効果を、前記ドーパミン作動性細胞のドーパミンを生成する又は代謝す る能力を測定することにより決定する請求の範囲第32項記載の方法。 34.神経疾患又は障害を治療するための治療用組成物であって、該組成物が線維 芽細胞成長因子ファミリーのメンバー及びトランスフォーミング成長因子ベータ ファミリーのメンバーの少なくとも1種を含む培養培地中において、インビトロ で培養した神経細胞由来の、分化する又は分化したドーパミン作動性細胞を含有 することを特徴とする組成物。 35.前記線維芽細胞成長因子ファミリーのメンバーがFGF−2であり、かつ前 記トランスフォーミング成長因子ベータファミリーのメンバーがアクチビン及び 骨形成タンパク質からなる群より選ばれる請求の範囲第34項記載の治療用組成 物。 36.前記培養培地が定義されている請求の範囲第34項又は35項記載の治療用 組成物。 37.前記神経細胞を前記患者のCNSから得る請求の範囲第34項〜26項のい ずれかに記載の治療用組成物。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33909094A | 1994-11-14 | 1994-11-14 | |
US08/339,090 | 1994-11-14 | ||
US08/482,079 US5981165A (en) | 1991-07-08 | 1995-06-07 | In vitro induction of dopaminergic cells |
US08/482,079 | 1995-06-07 | ||
PCT/CA1995/000636 WO1996015224A1 (en) | 1994-11-14 | 1995-11-14 | In vitro induction of dopaminergic cells |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007041989A Division JP2007135604A (ja) | 1994-11-14 | 2007-02-22 | ドーパミン作動性細胞のインビトロ誘導 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH10509319A true JPH10509319A (ja) | 1998-09-14 |
JP4023822B2 JP4023822B2 (ja) | 2007-12-19 |
Family
ID=26991488
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51559996A Expired - Fee Related JP4023822B2 (ja) | 1994-11-14 | 1995-11-14 | ドーパミン作動性細胞のインビトロ誘導 |
JP2007041989A Withdrawn JP2007135604A (ja) | 1994-11-14 | 2007-02-22 | ドーパミン作動性細胞のインビトロ誘導 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007041989A Withdrawn JP2007135604A (ja) | 1994-11-14 | 2007-02-22 | ドーパミン作動性細胞のインビトロ誘導 |
Country Status (10)
Country | Link |
---|---|
US (1) | US5981165A (ja) |
EP (1) | EP0792349A1 (ja) |
JP (2) | JP4023822B2 (ja) |
KR (1) | KR970707270A (ja) |
CN (1) | CN1170434A (ja) |
AU (1) | AU715246B2 (ja) |
CA (1) | CA2204629A1 (ja) |
FI (1) | FI971955A (ja) |
NO (1) | NO321000B1 (ja) |
WO (1) | WO1996015224A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004038018A1 (ja) | 2002-10-22 | 2004-05-06 | Eisai Co., Ltd. | 分裂停止後のドーパミン産生ニューロン前駆細胞に特異的に発現している遺伝子 |
WO2006009241A1 (ja) | 2004-07-22 | 2006-01-26 | Eisai Co., Ltd. | Lrp4/Corinドーパミン産生ニューロン前駆細胞マーカー |
JP2014515262A (ja) * | 2011-05-17 | 2014-06-30 | ユニバーシティ オブ セントラル フロリダ リサーチ ファウンデーション,インコーポレイテッド | 成体組織由来の安定した電気活性ニューロン |
JP2015180211A (ja) * | 2001-06-21 | 2015-10-15 | アステリアス バイオセラピューティクス インコーポレイテッド | パーキンソン病を治療するためのドーパミン作動性ニューロンおよび増殖能のある前駆細胞 |
Families Citing this family (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7544511B2 (en) * | 1996-09-25 | 2009-06-09 | Neuralstem Biopharmaceuticals Ltd. | Stable neural stem cell line methods |
US20010007657A1 (en) * | 1997-08-04 | 2001-07-12 | Reid James Steven | Compositions and methods for manipulating glial progenitor cells and treating neurological deficits |
US7795202B2 (en) * | 1997-08-04 | 2010-09-14 | Neurorepair, Inc. | Methods for treating a neurological disorder by peripheral administration of a transforming growth factor alpha (TGF-a) |
IL134289A0 (en) | 1997-08-04 | 2001-04-30 | Univ California | Methods for treating neurological deficits |
US20050096274A1 (en) * | 1998-04-07 | 2005-05-05 | Lough John W. | Bone morphogenetic protein and fibroblast growth factor compositions and methods for the induction of cardiogenesis |
US6277820B1 (en) | 1998-04-09 | 2001-08-21 | Genentech, Inc. | Method of dopaminergic and serotonergic neuron formation from neuroprogenitor cells |
US6787356B1 (en) | 1998-07-24 | 2004-09-07 | The United States Of America As Represented By The Department Of Health And Human Services | Cell expansion system for use in neural transplantation |
JP3291698B2 (ja) * | 1998-07-24 | 2002-06-10 | スティーブン・カーティン | 可変眼鏡用レンズ |
EP1109887A4 (en) * | 1998-07-29 | 2003-05-21 | Layton Bioscience Inc | PRODUCTION AND USE OF DOPAMINERGIC CELLS TO TREAT DOPAMINERGIC DEFICIENCIES |
US20020168766A1 (en) * | 2000-01-11 | 2002-11-14 | Gold Joseph D. | Genetically altered human pluripotent stem cells |
US7410798B2 (en) * | 2001-01-10 | 2008-08-12 | Geron Corporation | Culture system for rapid expansion of human embryonic stem cells |
US6667176B1 (en) * | 2000-01-11 | 2003-12-23 | Geron Corporation | cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells |
US6120528A (en) * | 1998-11-03 | 2000-09-19 | Hood Laboratories | Nipple assembly with endoscope |
WO2000047718A1 (en) * | 1999-02-11 | 2000-08-17 | The Salk Institute For Biological Studies | Isolation of stem cells and methods of use thereof |
CA2371241A1 (en) * | 1999-04-26 | 2000-11-02 | Stem Cell Pharmaceuticals, Inc. | Tgf-.alpha. polypeptides, functional fragments and methods of use therefor |
US20020099008A1 (en) | 1999-04-26 | 2002-07-25 | Daniel R. Twardzik | Method for stimulating hematopoiesis using tgf-alpha |
JP2002542818A (ja) * | 1999-05-03 | 2002-12-17 | カロリンスカ イノヴェーションズ アクツィエボラーグ | ニューロンの発生に関連する材料及び方法 |
AU2004202661B2 (en) * | 1999-05-03 | 2008-04-17 | Neuro Therapeutics Ab | Materials and methods relating to neuronal development |
US6749850B1 (en) | 1999-08-18 | 2004-06-15 | The General Hospital Corporation | Methods, compositions and kits for promoting recovery from damage to the central nervous system |
JP2003507349A (ja) * | 1999-08-18 | 2003-02-25 | ザ ゼネラル ホスピタル コーポレーション | 中枢神経系への損傷からの回復を促進する方法、組成物およびキット |
US20020193301A1 (en) * | 1999-08-19 | 2002-12-19 | Stem Cell Pharmaceuticals, Inc. | TGF-alpha polypeptides, functional fragments and methods of use therefor |
US6815418B2 (en) * | 1999-08-19 | 2004-11-09 | Kaleidos Pharma, Inc. | TGF-α polypeptides, functional fragments and methods of use therefor |
US6677307B2 (en) | 1999-08-19 | 2004-01-13 | Kaleidos Pharma, Inc. | TGF-α polypeptides, functional fragments and methods of use therefor |
US20050042749A1 (en) * | 2001-05-16 | 2005-02-24 | Carpenter Melissa K. | Dopaminergic neurons and proliferation-competent precursor cells for treating Parkinson's disease |
US7455983B2 (en) * | 2000-01-11 | 2008-11-25 | Geron Corporation | Medium for growing human embryonic stem cells |
US6395546B1 (en) * | 2000-02-01 | 2002-05-28 | Neurogeneration, Inc. | Generation of dopaminergic neurons from human nervous system stem cells |
EP1261357B1 (en) * | 2000-02-11 | 2010-07-14 | The Schepens Eye Research Institute, Inc. | Isolation and transplantation of retinal stem cells |
WO2001078752A2 (en) | 2000-04-13 | 2001-10-25 | Board Of Regents, The University Of Texas System | Treatment of disorders by implanting stem cells and/or progeny thereof into gastrointestinal organs |
JP5943533B2 (ja) | 2000-05-17 | 2016-07-06 | アステリアス バイオセラピューティクス インコーポレイテッド | 神経前駆細胞の集団 |
US6897061B1 (en) | 2000-06-16 | 2005-05-24 | Spinal Cord Society | Transdifferentiation of glial cells |
AU2001294647A1 (en) * | 2000-09-22 | 2002-04-02 | Stem Cell Pharmaceuticals, Inc. | Method or treatment of tumors using transforming growth factor-alpha |
AU2002251681A1 (en) * | 2000-12-05 | 2002-08-28 | Layton Bioscience Inc. | Production and use of dopaminergic cells to treat dopaminergic deficiencies |
US7838292B1 (en) | 2001-03-29 | 2010-11-23 | University Of Louisville Research Foundation, Inc. | Methods for obtaining adult human olfactory progenitor cells |
WO2002083877A1 (en) * | 2001-04-11 | 2002-10-24 | Stem Cell Therapeutics Inc. | Production of tyrosine hydroxylase positive neurons |
US20040247571A1 (en) * | 2001-04-23 | 2004-12-09 | Xia Meijer | Neural cells expressing tyrosine hydroxylase |
JP4824268B2 (ja) * | 2001-05-02 | 2011-11-30 | ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート | 学習および記憶を増強させるためのカルボニックアンヒドラーゼ活性化剤 |
WO2003014317A2 (en) * | 2001-08-08 | 2003-02-20 | Celmed Biosciences Usa | Compositions and methods for isolation, propagation, and differentiation of human stem cells and uses thereof |
US6825229B2 (en) | 2002-03-07 | 2004-11-30 | Blanchette Rockefeller Neurosciences Institute | Methods for Alzheimer's Disease treatment and cognitive enhancement |
US20080004332A1 (en) * | 2002-03-07 | 2008-01-03 | Alkon Daniel L | Methods for alzheimer's disease treatment and cognitive enhancement |
US20050065205A1 (en) * | 2002-03-07 | 2005-03-24 | Daniel Alkon | Methods for Alzheimer's disease treatment and cognitive enhance |
JP4439396B2 (ja) * | 2002-06-24 | 2010-03-24 | 田辺三菱製薬株式会社 | 神経系細胞の製造方法 |
AU2003296316A1 (en) * | 2002-12-09 | 2004-06-30 | The Mclean Hospital Corporation | Dopaminergic neurons differentiated from embryonic cells for treating neurodegenerative diseases |
EP1608728A2 (en) * | 2003-03-31 | 2005-12-28 | University Of South Florida Research Foundation, Inc. | Materials and methods for regulating process formation in cell culture |
ITRM20030376A1 (it) * | 2003-07-31 | 2005-02-01 | Univ Roma | Procedimento per l'isolamento e l'espansione di cellule staminali cardiache da biopsia. |
CN1867678B (zh) * | 2003-09-12 | 2012-10-03 | 干细胞技术公司 | 神经集落形成分析 |
US20070269412A1 (en) * | 2003-12-02 | 2007-11-22 | Celavie Biosciences, Llc | Pluripotent cells |
US7632681B2 (en) * | 2003-12-02 | 2009-12-15 | Celavie Biosciences, Llc | Compositions and methods for propagation of neural progenitor cells |
TW201206425A (en) * | 2004-05-18 | 2012-02-16 | Brni Neurosciences Inst | Treatment of depressive disorders |
US20060069009A1 (en) * | 2004-09-28 | 2006-03-30 | Messina Darin J | Treatment of neurological deficits in the striatum or substanta nigra pars compacta |
US11660317B2 (en) | 2004-11-08 | 2023-05-30 | The Johns Hopkins University | Compositions comprising cardiosphere-derived cells for use in cell therapy |
US7691629B2 (en) * | 2004-11-17 | 2010-04-06 | Neuralstem, Inc. | Transplantation of human neural cells for treatment of neurodegenerative conditions |
CA2617003A1 (en) | 2005-07-29 | 2007-02-08 | Blanchette Rockefeller Neurosciences Institute | Use of a pkc activator, alone or combined with a pkc inhibitor to enhance long term memory |
KR101240487B1 (ko) * | 2006-11-09 | 2013-03-08 | 더 존스 홉킨스 유니버시티 | 성체 포유동물 심근세포의 심장 줄기 세포로의 역분화 |
EP2959914A1 (en) | 2007-02-09 | 2015-12-30 | Blanchette Rockefeller Neurosciences, Institute | Therapeutic effects of bryologs on head trauma-induced memory impairment and brain injury |
US8338176B2 (en) * | 2007-07-30 | 2012-12-25 | The Board Of Trustees Of The Leland Stanford Junior University | Derivation of neural stem cells from embryonic stem cells |
US9101570B1 (en) | 2009-02-13 | 2015-08-11 | Endocellutions, Inc. | Adult and neonatal stem cell therapy to treat diabetes through the repair of the gastrointestinal tract |
US20100209399A1 (en) * | 2009-02-13 | 2010-08-19 | Celavie Biosciences, Llc | Brain-derived stem cells for repair of musculoskeletal system in vertebrate subjects |
GB0908934D0 (en) * | 2009-05-26 | 2009-07-01 | Univ The West Of Scotland | Differentiation medium |
US9249392B2 (en) | 2010-04-30 | 2016-02-02 | Cedars-Sinai Medical Center | Methods and compositions for maintaining genomic stability in cultured stem cells |
US9845457B2 (en) | 2010-04-30 | 2017-12-19 | Cedars-Sinai Medical Center | Maintenance of genomic stability in cultured stem cells |
NZ623207A (en) | 2010-07-28 | 2014-12-24 | Neuralstem Inc | Methods for treating and/or reversing neurodegenerative diseases and/or disorders |
CN103031335A (zh) * | 2011-10-09 | 2013-04-10 | 李川源 | 直接从人成纤维细胞诱导产生多巴胺样神经元的方法及应用 |
WO2013123292A1 (en) | 2012-02-17 | 2013-08-22 | The Schepens Eye Research Institute | Phenotype profile of human retinal progenitor cells |
EP2861238A4 (en) | 2012-06-05 | 2016-03-16 | Capricor Inc | OPTIMIZED METHODS FOR GENERATING CARDIAC STEM CELLS FROM CARDIAC TISSUE AND THEIR USE IN CARDIAC THERAPY |
EP2882445B1 (en) | 2012-08-13 | 2019-04-24 | Cedars-Sinai Medical Center | Exosomes and micro-ribonucleic acids for tissue regeneration |
AU2015327812B2 (en) | 2014-10-03 | 2021-04-15 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy |
JP6983069B2 (ja) | 2014-10-20 | 2021-12-17 | ニューラルステム, インコーポレイテッド | 成長因子をコードする外因性ポリヌクレオチドを含む安定な神経幹細胞およびその使用の方法 |
US10520493B2 (en) * | 2015-03-13 | 2019-12-31 | National Cheng Kung University | Method for assessment of neural function by establishing analysis module |
WO2017123662A1 (en) | 2016-01-11 | 2017-07-20 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction |
US11351200B2 (en) | 2016-06-03 | 2022-06-07 | Cedars-Sinai Medical Center | CDC-derived exosomes for treatment of ventricular tachyarrythmias |
WO2018057542A1 (en) | 2016-09-20 | 2018-03-29 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and their extracellular vesicles to retard or reverse aging and age-related disorders |
AU2018255346B2 (en) | 2017-04-19 | 2024-05-02 | Capricor Inc | Methods and compositions for treating skeletal muscular dystrophy |
WO2019126068A1 (en) | 2017-12-20 | 2019-06-27 | Cedars-Sinai Medical Center | Engineered extracellular vesicles for enhanced tissue delivery |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5082670A (en) * | 1988-12-15 | 1992-01-21 | The Regents Of The University Of California | Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system |
JP3187410B2 (ja) * | 1989-08-10 | 2001-07-11 | 住友製薬株式会社 | 脳内投与用徐放性製剤 |
US5411883A (en) * | 1989-12-26 | 1995-05-02 | Somatix Therapy Corporation | Proliferated neuron progenitor cell product and process |
WO1991009936A1 (en) * | 1989-12-26 | 1991-07-11 | Hana Biologics, Inc. | Proliferated neuron progenitor cell product and process |
EP0594669B9 (en) * | 1991-07-08 | 2008-03-19 | NeuroSpheres Holdings Ltd. | Growth factor-responsive neural progenitor cells which can be proliferated in vitro. |
HU220795B1 (hu) * | 1991-09-20 | 2002-05-28 | Amgen Inc. | Gliasejtvonal-eredetű neurotróf faktorfehérjék, továbbá berendezések és gyógyászati készítmények idegsejtkárosodás megelőzésére és kezelésére |
AU4995193A (en) * | 1992-08-04 | 1994-03-03 | Regeneron Pharmaceuticals, Inc. | Method of enhancing differentiation and survival of neuronal precursor cells |
DK0669973T4 (da) * | 1992-10-28 | 2007-08-27 | Neurospheres Holdings Ltd | Biologiske faktorer og neurale stamceller |
-
1995
- 1995-06-07 US US08/482,079 patent/US5981165A/en not_active Expired - Fee Related
- 1995-11-14 EP EP95936392A patent/EP0792349A1/en not_active Withdrawn
- 1995-11-14 JP JP51559996A patent/JP4023822B2/ja not_active Expired - Fee Related
- 1995-11-14 WO PCT/CA1995/000636 patent/WO1996015224A1/en not_active Application Discontinuation
- 1995-11-14 CA CA002204629A patent/CA2204629A1/en not_active Abandoned
- 1995-11-14 AU AU38366/95A patent/AU715246B2/en not_active Ceased
- 1995-11-14 CN CN95196843A patent/CN1170434A/zh active Pending
- 1995-11-14 KR KR1019970703244A patent/KR970707270A/ko not_active Application Discontinuation
-
1997
- 1997-05-07 FI FI971955A patent/FI971955A/fi not_active Application Discontinuation
- 1997-05-12 NO NO19972170A patent/NO321000B1/no unknown
-
2007
- 2007-02-22 JP JP2007041989A patent/JP2007135604A/ja not_active Withdrawn
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015180211A (ja) * | 2001-06-21 | 2015-10-15 | アステリアス バイオセラピューティクス インコーポレイテッド | パーキンソン病を治療するためのドーパミン作動性ニューロンおよび増殖能のある前駆細胞 |
WO2004038018A1 (ja) | 2002-10-22 | 2004-05-06 | Eisai Co., Ltd. | 分裂停止後のドーパミン産生ニューロン前駆細胞に特異的に発現している遺伝子 |
WO2006009241A1 (ja) | 2004-07-22 | 2006-01-26 | Eisai Co., Ltd. | Lrp4/Corinドーパミン産生ニューロン前駆細胞マーカー |
JP2014515262A (ja) * | 2011-05-17 | 2014-06-30 | ユニバーシティ オブ セントラル フロリダ リサーチ ファウンデーション,インコーポレイテッド | 成体組織由来の安定した電気活性ニューロン |
Also Published As
Publication number | Publication date |
---|---|
NO972170D0 (no) | 1997-05-12 |
KR970707270A (ko) | 1997-12-01 |
NO972170L (no) | 1997-06-30 |
US5981165A (en) | 1999-11-09 |
NO321000B1 (no) | 2006-02-27 |
JP2007135604A (ja) | 2007-06-07 |
MX9703493A (es) | 1997-10-31 |
WO1996015224A1 (en) | 1996-05-23 |
AU3836695A (en) | 1996-06-06 |
CN1170434A (zh) | 1998-01-14 |
EP0792349A1 (en) | 1997-09-03 |
FI971955A0 (fi) | 1997-05-07 |
CA2204629A1 (en) | 1996-05-23 |
JP4023822B2 (ja) | 2007-12-19 |
AU715246B2 (en) | 2000-01-20 |
FI971955A (fi) | 1997-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4023822B2 (ja) | ドーパミン作動性細胞のインビトロ誘導 | |
ES2194016T5 (es) | Factores biologicos y celulas germinales neurales. | |
AU665012B2 (en) | Novel growth factor-responsive progenitor cells which can be proliferated (in vitro) | |
CA2307017C (en) | Erythropoietin-mediated neurogenesis | |
AU2002324645B2 (en) | Compositions and methods for isolation, propagation, and differentiation of human stem cells and uses thereof | |
US6878543B1 (en) | Cultures of GFAP+ nestin+ cells that differentiate to neurons | |
AU2002324645A1 (en) | Compositions and methods for isolation, propagation, and differentiation of human stem cells and uses thereof | |
EP0783693B1 (en) | In vitro models of cns function and dysfunction | |
MXPA97002126A (es) | Modelos in vitro de funcion y disfuncion del snc | |
JP3636474B2 (ja) | 正常神経上皮前駆細胞 | |
Bottenstein | Environmental influences on cells in culture | |
MXPA97003493A (en) | In vitro induction of dopaminergi cells | |
Ueda et al. | Neuro-glial neurotrophic interaction in the S-100β retarded mutant mouse (Polydactyly Nagoya). III. Transplantation study | |
Ronnett | Human Neuronal Cell Lines as in Vitro Models | |
Class | Patent application title: COMPOSITIONS AND METHODS FOR ISOLATION, PROPAGATION, AND DIFFERENTIATION OF HUMAN STEM CELLS AND USES THEREOF Inventors: Toomas Neuman (Santa Monica, CA, US) Michel Levesque (Beverly Hills, CA, US) Assignees: LEVESQUE BIOSCIENCES, INC. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20040413 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040427 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20040727 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20040913 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20041027 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060822 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20061117 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070105 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070222 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20070904 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20071002 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101012 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111012 Year of fee payment: 4 |
|
LAPS | Cancellation because of no payment of annual fees |